Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: A systematic review

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 11, 2013, Pages 2644-2650

  Qu, Hongying ^a,b   Li, Rong ^a   Liu, Zhiyue ^c   Zhang, Junyi ^a   Luo, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b BAOTOU MEDICAL COLLEGE   (China)

^c INNER MONGOLIA MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells; CD133; Non small cell lung cancer; Prognosis

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

CANCER GRADING; CANCER STAGING; CANCER STEM CELL; CD133; CHI SQUARE DISTRIBUTION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS; METABOLISM; MORTALITY; NON-SMALL CELL LUNG CANCER; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REVIEW; RISK; RISK FACTOR;

CANCER STEM CELLS; CD133; NON-SMALL CELL LUNG CANCER; PROGNOSIS;

ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; ODDS RATIO; PEPTIDES; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887089570     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Nguyen LV, Vanner R, Dirks P and Eaves CJ. Cancer stem cells:an evolving concept. Nat Rev Cancer 2012;12:133-43.
3. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L and Moore MA. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 2000;95:952-958.
4. O'Brien CA, Pollett A, Gallinger S and Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2006;445:106-110.
5. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14.
6. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.
7. Horst D, Kriegl L, Engel J, Kirchner T and Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-9.
8. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B and Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-9.
9. Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta -analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
10. Zhang HZ, Wei YP, Wang M, Wu C, Yang YQ, Chen J, Cao YK. Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2007;27:696-9.
11. Wei YP, et al. Expression of Tumor Stem Cell Marker CDl33 in Non-small Cell Lung Carcinoma and Its Clinical Significance. Journal of Sun Yat-sen University (Medical Sciences) 2008;29:312-316.
12. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J and Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non -small cell lung cancer patients. Int J Cancer 2010;126:950-8.
13. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G and Pirozzi G. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009;36:446-53.
14. Xu YH, Zhang GB, Wang JM and Hu HC. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J 2010;31:980-986.
15. Chen JR, et al. Expressions of CDl33 and CDl05 in lung cancer tissue and their clinical significance. Tumor 2010;30:334-337.
16. Ni JY, et al. Expression and significance of OCT4, CD133 in non-small cell lung cancer. Journal of Clinical Medicine in Practice 2012;16:19-22.
17. Li F, Zeng H and Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 2011;28:1458-62.
18. Sun HY, et al. Expression and significance of CD133 and ALDH1 in non-small cell lung cancer. J Clin Exp Pathol 2012;28:813-815.
19. Wang SG, Zeng ZY, Yang SS, Lin JS, Yuan Y. The study of CD133 expression in 83 cases of human lung adenocarcinoma cells. Journal of Cardiovascular and Pulmonary Diseases 2012;31:727-729.
20. Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E, Kinoshita I, Oizumi S, Dosaka-Akita H, Matsuno Y, Nishimura M. CD133 expression:a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol 2013;1-6.
21. Weigmann A, Corbeil D, Hellwig A and Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA 1997;94:12425-30.
22. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK and Buck DW. A novel five-transmembrane hematopoietic stem cell antigen:isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021.
23. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-50.
24. Zhao P, Li Y and Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010;10:218.
25. Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M and Ohashi K. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and ß -catenin, in primary lung adenocarcinoma- their prognostic significance. Pathol Int 2012;62:792-801.
26. Simon R and Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979.
27. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C and Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-329.